Monjaro or tirzepatide: understanding the medicine behind the name

The spelling confusion — and why it matters for buying safely

"Monjaro" (without the 'u') is one of the most common misspellings of Mounjaro, alongside variations like "munjaro" and "monjaro tirzepatide". It happens because the brand name is unfamiliar and people type quickly. The clinical substance behind every correct spelling is tirzepatide, and if you want to read more about the medicine itself, our Mounjaro page covers what it is and how it is used. If you want to read more about that in detail, the tirzepatide overview page covers how it works at the receptor level.

The reason spelling matters here is not pedantry. Counterfeit weight-loss pens are sold online using misspellings and lookalike listings as a way to reach people who aren't yet confident in the exact name. The MHRA has warned publicly about fake pens, some have contained insulin rather than tirzepatide, leading to serious harm. Any seller offering this medicine without a clinical assessment from a registered prescriber is a red flag, whatever spelling they use. Genuine Mounjaro is only available on prescription, through a pharmacy you can verify on the GPhC register at pharmacyregulation.org/registers.

So: monjaro, mounjaro, tirzepatide and Mounjaro are the same medicine. One safe route.

How tirzepatide actually works, and why the dual-receptor mechanism is significant

Most GLP-1 medicines work on a single receptor. Tirzepatide activates two: GLP-1 and GIP. Both are gut hormones involved in appetite signalling, blood-sugar regulation, and how quickly food moves through the stomach. Together they produce a stronger and more sustained reduction in appetite than either pathway alone, which is reflected in the trial data.

In SURMOUNT-1, a 72-week trial involving 2,539 adults with obesity and no diabetes, participants on the 15mg dose lost an average of around 20-21% of their starting body weight. That evidence informed NICE's recommendation of tirzepatide in December 2024, you can read the full appraisal at NICE TA1026. For context on how tirzepatide compares with semaglutide, the Mounjaro or tirzepatide comparison page sets out what the evidence actually shows.

Treatment starts at 2.5mg (a dose chosen to let your body adjust rather than to drive weight loss) and is titrated by the prescriber, typically in monthly steps, with our tirzepatide dose guide explaining how each stage of the titration is structured. Your pen lives in the fridge between uses, which for most people means a corner of the fridge door becomes its weekly home. The NHS tirzepatide medicines page has a clear summary of the side effects and storage guidance worth reading before you start.

Who this medicine is and isn't for (the eligibility picture

The UK licence covers adults with a BMI of 30 or above, or 27 and above if there is at least one weight-related condition) for example, high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE's guidance, reflecting differences in health risk at a given BMI. A number on a calculator alone does not decide the outcome: the prescriber looks at your full health picture, including any medicines you already take.

Tirzepatide is not suitable during pregnancy or breastfeeding, and is not recommended if you are trying to conceive. It is not licensed for people under 18. Certain medical histories (including pancreatitis and some thyroid conditions) require careful discussion with a prescriber before any decision is made. If you want to understand how the highest maintenance dose fits into a full treatment course, the tirzepatide 30 page explains what that stage of treatment involves and why cost figures vary.

The point of a clinical consultation is exactly this: matching the evidence base to your circumstances, not issuing a prescription by default. Our prescribers at our clinical team page explains who reviews your case.

Common side effects and what the monitoring picture looks like

The most frequently reported effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion, and burping are the ones people mention most. They are typically at their worst in the first days after starting or after a dose increase, and most people find them settle considerably within one to two weeks. Slowing down eating, keeping portions modest, and staying hydrated all help.

There are some effects worth knowing about before you start. The MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk for people on GLP-1 medicines: severe stomach pain that extends towards the back, particularly if it persists, needs prompt medical attention rather than waiting to see if it passes. Gallbladder symptoms (sharp upper-right abdominal pain) are also flagged in the safety data. Suspected side effects can be reported directly to the MHRA via the Yellow Card scheme.

Mounjaro carries a Black Triangle (▼) designation, meaning pharmacovigilance continues actively while real-world data builds. This is standard for newer medicines and does not mean it is unsafe, it means the MHRA wants a complete picture, and that picture grows with every treated patient who reports their experience. If you are ready to have a prescriber review your suitability, check your eligibility through our free consultation.